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Mutations in the TNF family ligand EDA1
cause X-linked hypohidrotic ectodermal
dysplasia (XLHED), a condition characterized
by defective development of skin appendages.
The EDA1 protein displays a proteolytic
processing site responsible for its conversion to
a soluble form, a collagen domain and a
trimeric TNF homology domain (THD) that
binds the receptor EDAR.
In frame deletions in the collagen domain
reduced the thermal stability of EDA1.
Removal of the collagen domain decreased its
activity about 100-fold, as measured with
natural and engineered EDA1-responsive cell
lines. The collagen domain could be
functionally replaced by multimerization
domains or by cross-linking antibodies,
suggesting that it functions as an
oligomerization unit. Surprisingly, mature
soluble EDA1 containing the collagen domain
was poorly active when administered in
newborn, EDA-deficient (Tabby) mice. This was
due to a short stretch of basic amino acids
located at the N-terminus of the collagen
domain that confers EDA1 with proteoglycan-
binding ability. In contrast to wild type EDA1,
EDA1 with mutations in this basic sequence
was a potent inducer of tail hair development in
vivo. Thus, the collagen domain activates EDA1
by multimerization, whereas the proteoglycan-
binding domain may restrict the distribution of
endogeneous EDA1 in vivo.
TNF family ligands spontaneously form
homotrimers that can bind three individual
receptors (1). For some family members, these
trimeric complexes are biologically active. For
example, trimers of TNF and TWEAK (TNF
homologue with weak apoptosis inducing activity)
signal cell death in their respective target cells,
and cross-linking of several trimers, via the action
of an anti-Flag antibody, does not result in
increased activity (2). For other ligands, the
trimeric, soluble complexes are not or only poorly
biologically active, but their membrane-bound
forms are. This is the case, among others, for FasL
and CD40L. These ligands can however become
active in a soluble form if trimers are cross-linked,
either with antibodies, or by fusion with
oligomerizing proteins, such as the Fc portion of
an immunoglobulin, or the collagen domain of
ACRP/adiponectin (2,3).
Ectodysplasin A (EDA) is a TNF family ligand
involved in the development of various structures
derived from the ectoderm, such as hair, teeth and
sweat glands, and EDA loss of function in mouse
2and human is associated with X-linked
hypohidrotic ectodermal dysplasia (OMIM
305100). Of the several EDA isoforms that have
been described, two of which comprise the TNF
homology domain, only EDA1 has been
implicated in the development of ectodermal
appendages (4,5). Activation of the NF-κB
transcription factor through the EDA1 receptor
(EDAR) is a central signaling event as suggested
by the ectodermal dysplasia phenotype of NF-κB
compromised mice (6), and by the fact that early
events of placode formation can be initiated by
EDAR-independent NF-κB signals (7). One
relevant NF-κB target downstream of EDAR is
CTGF/CCN2 (connective tissue growth
factor/CCN family protein2) that locally
counteracts inhibitors of placode fate, thus
allowing placode formation at the site of EDAR
signaling in embryonic skin (8,9).
Several lines of evidence indicate that EDA1
trimers must probably be aggregated in order to
signal. First, EDA1 possesses a collagen domain
that may potentially aggregate the TNF homology
domain (10). Second, inactive trimeric FasL is
partially activated by fusion with the collagen
domain of EDA1 (11). Third, a number of X-
linked hypohidrotic ectodermal dysplasia (XL-
HED) patients have point mutations or in frame
deletions in the collagen domain that suggest this
domain fulfills a functional role (11). Fourth,
fusion of the EDA1 receptor-binding domain to
the Fc portion of an immunoglobulin yields a
biologically active ligand (12). However, it has
never been formally demonstrated that EDA1
needs to be cross-linked in order to be active, and
that the collagen domain of EDA1 fulfills this
cross-linking function.
Using an EDA1-dependent NF-κB activation
assay in HaCat keratinocytes and a specific
biological assay to measure oligomerization of
EDA1 trimers, we demonstrate here that the
collagen domain is required for EDA1 to signal
efficiently through EDAR. This function of the
collagen domain can be mimicked by antibody-
mediated cross-linking, or by fusion of the TNF
homology domain of EDA1 to the Fc portion of
human immunoglobulin G1. In vivo, the biological
activity of exogenously administered EDA1 is also
dependent on multimerization, but to a lesser
extent than predicted by in vitro results, and is
additionally negatively regulated by a newly
identified, evolutionarily conserved heparan
sulfate proteoglycan (HSPG)-binding region that
may restrict bio-distribution of the protein.
MATERIALS AND METHODS
Cells  - 293T cells were grown in DMEM
supplemented with 10% of heat-inactivated fetal
calf serum (FCS). HaCat cells were grown in
DMEM : NutMix-F12 (1:1, v/v), 5% FCS, 50
U/ml penicillin and streptomycin, 9 ng/ml of
cholera toxin (Sigma), 5 µg/ml of insulin (Sigma),
24.3 µg/ml of adenosine (Sigma), 10 ng/ml of
epidermal growth factor (Sigma) and 0.5 µg/ml of
hydroxycortisone (Sigma). Jurkat and Jurkat-
EDAR:Fas cells were grown in RPMI
supplemented with 10% FCS.
Cells were passaged twice weekly. HaCat cells
were trypsinized. When cells were analyzed by
FACS, however, they were detached with PBS, 1
mM EDTA.
Generation of EDAR:Fas Jurkat cells -
Retroviruses were produced essentially as
described previously (13). Briefly, 293T cells were
transiently transfected with pMSCVpuro-
EDAR:Fas and co-transfected with the pHIT60
and VSV-G plasmids, containing the sequences
for gag-pol and VSV-G, respectively.
pMSCVpuro-EDAR:Fas encodes the extracellular
domain of human EDAR (amino acids 1-183),
amino acids VD and the transmembrane and
intracellular domains of human Fas (amino acids
169-335). After transfection, 293T cells were
incubated for 24 h in RPMI supplemented with
10% FCS. Fas-deficient Jurkat-JOM2 cells were a
kind gift of Olivier Micheau (University of Dijon,
France). Jurkat-JOM2 cells (106 cells in 1 ml)
were mixed with virus-containing supernatants (3
ml) supplemented with 8 µg/ml of polybrene, left
for 15 min at 37°C, and centrifuged for 1 h at
37°C and at 450 x g (1500 rpm). Cells were
selected with 5 µg/ml of puromycin and cloned.
About 40 clones were tested for their sensitivity to
Fc-EDA1 (12,14), and one of the sensitive clones
(Jurkat-2199 clone 23) was selected for further
experimentation.
HaCat IκBα -DN cells were generated in a
similar way using pMSCVpuro-IκBα-S32G
3vector, except that cells were not cloned but used
as a population.
 Expression constructs - Expression constructs
were cloned into the PCR3 mammalian expression
vector (Invitrogen) according to standard
molecular biology techniques. Vector for
expression of Flag-tagged ligands, ACRP-ligands,
Fc-ligands, receptors-Fc, receptors-GPI and
receptors-COMP-Flag have been described
previously (3,14-16). Fc-ligands with a
PreScission protease cleavage site were
constructed by insertion of the Prescission site in
the Fc-ligand vector. Details regarding plasmids
used in this study and the proteins they encode are
provided in Suppl. Table 1 and Figure 1,
respectively.
Calcium phosphate transfection of 293T cells -
106 293T cells were seeded in 8 ml medium in a
10 cm diameter dish and transfected
approximately 8 h later. The transfection was
performed by mixing 7 µg of plasmid of interest
and 1 µg of EGFP tracer plasmid with 50 µl of 2.5
M CaCl2. Sterile water was then added to 500 µl.
While vortexing the DNA mix, 500 µ l of 2 x
HeBS buffer was added dropwise (16.4 g NaCl,
11.9 g Hepes, acid form, 0.21 g Na2HPO4, 800 ml
H2O, adjusted to pH 7.05 with NaOH, and finally
brought to 1L and filtrated). The transfection mix
was added to cells within 1 minute after mixing.
The next day, cells were washed with PBS and 8
ml of fresh medium was added (DMEM 10% FCS
or serum-free Opti-MEM1 medium).
HaCat cell stimulation assay - Two days before
stimulation, cells were seeded in 24 well plates
(105 cells/well). The day before stimulation, cells
were starved overnight in serum-free DMEM
medium, 50 U/ml penicillin and streptomycin. On
the day of stimulation, medium was removed and
0.5 to 1 ml of fresh DMEM (no serum) was added
that contained the ligand of interest either in a
purified form (between 0.05 and 1µg/ml) or as
Opti-MEM supernatants.
Immunoprecipitations of recombinant EDA1
from cell culture supernatant - Conditioned Opti-
MEM supernatant was concentrated 20 times in
Amicon Ultra filter devices (molecular weight cut
off of 10000 Da).  Immunoprecipitations were
performed on 200 to 400 µl of Opti-MEM
supernatant (or 10 to 20 µl of concentrated Opti-
MEM) with 10 µl of Protein A-Sepharose beads.
One µg of hEDAR-Fc was added if the target
EDA1 protein did not contain an Fc moiety. PBS
was added to a final volume of 400 µl and the
mixture was incubated for 1 hour at 4°C on a
rotating wheel. Beads were washed twice with 1
ml of PBS, and transferred into a mini column
made of a 200 µl tip plugged with a 1 mm
diameter “stopper”, eluted with 15 to 20 µl of 100
mM Na-citrate pH 4, and neutralized with the
appropriate volume of 1 M Tris-HCl pH 9.
For heparin-Sepharose pull-downs (GE
Healthcare), 10 µl of beads freshly re-hydrated in
PBS were mixed with 750 µl of Opti-MEM
supernatant in PBS (1:1 vol/vol), incubated for 1 h
at 4°C on a rotating wheel, transferred into a mini
column, whased with PBS and eluted with 15 µl of
PBS supplemented with 0.8 M NaCl.
Cell lysis - HaCat cells were harvested at defined
time points. Plates were put on ice, cells were
washed once with ice-cold PBS and lysed in 50 µl
of lysis buffer (1% Triton-X100, 5 mM 2-
glycerophosphate, 10 mM NaF, 1 mM Na3VO4, 1
mM dithiothreitol, and one tablet/50 ml of
Cømplete protease inhibitor (Roche, Basel,
Switzerland)). Plates were briefly vortexed, cells
were scraped from the plate and the lysates were
centrifuged for 5 minutes at 4°C and 13000 rpm
(16000 x g) in a tabletop centrifuge. Protein
concentration in cell lysate supernatants was
determined with the BCA assay (Pierce, Rockford,
IL, USA).
SDS-PAGE and Western blotting - Proteins were
resolved by 12% SDS-PAGE and transferred onto
nitrocellulose membranes. The following primary
antibodies were used: rabbit anti-EDA1 serum
AL166 (11), mouse monoclonal antibody anti-P
IκBα  mouse (Cell Signaling, Beverly, MA),
polyclonal rabbit antibody anti-IκBα (Santa Cruz,
Santa Cruz, CA), mouse monoclonal antibody
anti-α-tubulin (Sigma, St-Louis, MO), M2 mouse
monoclonal antibody anti-Flag (Sigma, St-Louis,
MO) and horse radish peroxydase-coupled
an t ibody  an t i -human IgG ( Jackson
4ImmunoResearch). Blots were revealed with ECL
(GE Healthcare).
Purification of Flag-tagged proteins - Various
Flag-tagged EDA1 constructs were purified from
supernatants of transiently transfected 293T cells
using anti-Flag M2-agarose (Sigma). Flag-EDA1
were eluted with citrate-NaOH pH 3 and
neutralized with Tris-HCl pH 9. Buffer was
exchanged for PBS, and the protein was stored at -
70°C until use.
Purification of Fc-tagged proteins - Fc-
PreScission-EDA1-E245, Fc-EDA-A238 and
hEDAR-PreScission-Fc proteins were purified
from culture supernantants of stably transfected
CHO cell clones by Protein-A affinity
chromatography (15).
Cytotoxicity assays - The cytotoxicity assay
using EDAR:Fas Jurkat cells was performed as
described for FasL on Jurkat cells (2).
Prescission protease digestion of proteins -
Proteins were digested in PBS 1 mM EDTA with
40 U/ml of GST-Prescission protease (GE
Healthcare). Digestions were performed either in
solution or on Protein A-Sepharose beads for 24
hours at 4°C on a rotating wheel. Digestion
efficiency was checked by Western blotting with
anti-EDA1 antibodies.
Gel filtration chromatography and enzyme-linked
immunosorbant assay - 100 µg of Fc-PreScission-
EDA1-E245 (cleaved or not with PreScission
protease), were applied onto a Superdex 200
column (GE Healthcare) and eluted in PBS at 0.5
ml/min. Fractions of 250 µl were collected, of
which 10 µl were analyzed by Western blotting.
Various Flag-EDA and Flag-FasL constructs in
Opti-MEM supernatants were analyzed similarly.
In this case, 2, 5, 10 or 50 µl of the 500 µl
fractions were used to detect the ligands by
ELISA, essentially as described previously (3,11).
Briefly, EDAR-Fc or Fas-Fc (Alexis, Lausen,
Switzerland) were coated at 1 µg/ml to capture the
ligands, and biotinylated anti-Flag M2 antibody
(Sigma) followed by horse radish peroxydase-
coupled streptavidin were used for revelation. The
Superdex 200 column was calibrated with the
following standard proteins: thyroglobulin (669
kDa), ferritin (440 kDa), catalase (232 kDa),
aldolase (158 kDa), bovine serum albumin (67
kDa) ovalbumin (43 kDa), chymotrypsinogen A
(25 kDa) and ribonuclease A (13.7 kDa).
Flow cytometry analysis - HaCat cells were
detached with PBS, 1 mM EDTA, and washed
once with FACS buffer (PBS, 1% FCS). Staining
was performed in 96 well plates with 0.5 x 106 to 1
x 106 cells/well, using 10 µl of Fc-PS-EDA1-E245
Opti-MEM supernatant and 40 µl FACS buffer,
for 20 minutes at 4°C. In some instances, FACS
buffer was replaced by 20-fold concentrated Opti-
MEM supernatant containing the soluble receptors
EDAR-COMP-Flag or BCMA-COMP-Flag. After
washing with FACS buffer, Fc-EDA1 was
revealed with phycoerythrin (PE)-coupled anti-
human Fc antibodies (Southern Biotech,
Birmingham, AL).
293T cells co-transfected with EDAR-GPI (or
XEDAR-GPI control) and EGFP, and Jurkat cells
transfected with syndecan-1, syndecan-2 or
glypican-1 expression constructs, were stained
with various Fc-ligands or Flag-ligands as
described previously (14).
Intraperitoneal injections in newborn Tabby
mice - Tabby mice (Jackson Laboratories, Bar
Harbour) were handled according to institutional
and Swiss Federal Veterinary Office guidelines,
with the authorization of the Office vétérinaire
cantonal du canton de Vaud.
Pups were labeled by puncture of a footpad with
a 30 Gauge needle dipped in Aramis tattoo ink
(Braintree Scientific,  Braintree, MA).
Intraperitoneal injections of EDA1 proteins were
performed within 24 h after birth with a maximal
volume of 15 µ l using 0.5 ml U-100 Insulin
syringe (Becton Dickinson, Franklin Lakes, NJ).
When two injections were required, Fc-EDA1 and
EDAR-Fc were each administered in 7.5 µl.
Examination and photography of tail hairs were
performed 3 to 4 weeks post injection.
Genotyping - TNF-/- mice (17) were kindly
provided by Dr Fabienne Tacchini-Cottier. The
following pairs of oligonucleotides were used for
g e n o t y p i n g :  T N F-/-:  5 ' -
AGGGCTGTGGGACCTAAATGTC-3' and 5'-
TTTGAAGCGTGCGAGAATGC-3'. TNF+/+: 5'-
5AGGGCTGTGGGACCTAAATGTC-3' and 5'-
TTTGAGTTCTTGGAGGAAGTGGC-3'.
RESULTS
HaCat cells express EDAR and activate NF-κB
in response to EDA1 stimulation - HaCat cells
have been shown previously to express messenger
RNA for EDAR (18). We have used a fusion
protein, in which the receptor-binding portion of
EDA1 was fused to the Fc portion of human
immunoglobulin G1 (Fc-EDA1) (12), as a probe to
detect surface expression of EDAR in HaCat cells
(Fig. 2A). As expected for a specific interaction,
this staining was dose-dependent (Fig. S1) and
could be competed by pre-incubation of Fc-EDA1
with a soluble form of recombinant EDAR, but not
by pre-incubation with an irrelevant receptor (Fig.
2A). We conclude that HaCat cells express
endogenous EDAR at the cell surface.
In order to determine whether EDA1 or TNF
could activate NF-κB signaling in HaCat cells, the
phosphorylation and degradation of the NF-κB
inhibitor IκBα (19) was assessed following EDAR
or TNF receptor engagement. HaCat cells were
starved in serum-free medium to down-regulate
spontaneous NF-κB activation, and subsequently
stimulated with TNF as a positive control for NF-
κ B activation.  TNF induced robust
phosphorylation of IκBα within five minutes. This
event was followed by the degradation of IκBα, as
observed after 15 and 30 minutes, and its re-
synthesis after 1 and 4 hours (Fig. 2B). Discrete
upper bands of phospho-IκBα detected at 5
minutes most probably represent ubiquitin
derivatives of IκB α  that are targeted to
degradation (19). Compared to untreated control
cells, biologically active Fc-EDA1 (12) also
induced some IκBα phosphorylation, although the
response was weaker and slower than with TNF,
and the disappearance of IκBα was at best partial
at later time points (Fig. 2B).
These results indicate that HaCat cell can
respond to biologically active EDA1.
EDAR does not signal cell death in HaCat cells
and does not rescue putative TNF-induced cell
death during embryonic development -  Mouse
embryos with impaired NF-κB signaling suffer
from massive liver damage and die at around
gestational day 15, but can be rescued by TNF or
TNF-R1 inactivation, indicating that TNF is the
cause of liver damage (20,21). When NF-κB is
compromised, TNF-R1 signals apoptosis through a
death domain-dependent secondary signaling
complex (22). As EDAR resembles TNF-R1 not
only by its ability to activate NF-κB, but also by
the presence of an intracellular death domain, we
wondered whether EDA1 could negatively affect
viability of HaCat cells with compromised NF-κB
signaling. HaCat cells expressing a super-repressor
of NF-κB (non-degradable IκBα) died as expected
in response to TNF, but remained completely
resistant to EDA1, suggesting that EDAR does not
transmit death signals similar to TNF-R1 (Fig.
S2A).
Nevertheless, cells involved in early placode
development could be killed in a TNF-dependent
manner in the absence of protective, EDAR-
mediated NF-κB signals, as observed for fetal
liver cells in response to TNF (20,21). In this
scenario, EDA-deficiency should be rescued by
concomitant inactivation of TNF. This was
however experimentally not the case, as EDA-
deficient mice expressing TNF or not both
displayed identical phenotype of ectodermal
dysplasia (Fig. S2B).
The TNF homology domain of EDA1 is a poor
NF-κB agonist compared to longer forms of EDA1
- Although the THD of EDA1 (EDA-E245) is both
required and sufficient to bind EDAR (11) (Fig.
S3B), high concentration of this ligand was
required to induce only a weak NF-κB signal in
HaCat cells (Fig. 3A). In contrast, a longer form of
EDA1 starting at the furin cleavage site (EDA1-
S160) and comprising the collagen domain in
addition to the THD was estimated to be at least
100-fold more potent than EDA1-E245 in this NF-
κB assay (Fig. 3A and Fig. S3A). The same was
true for naturally processed EDA1 (Fig. 3B). Of
note, EDA1-S160 constructs with in-frame
deletions in the collagen domain (Δ185-196 and
Δ218-223) were as efficient as the wild type
protein in this assay (Fig. 3A and B).
These results indicate that the presence of the
collagen domain increases the biological activity
of EDA1 about 100-fold, regardless of whether or
not it contains short in frame deletions.
6Cross-linking antibodies can functionally replace
the collagen domain of EDA - Results presented
above indicate that the collagen domain of EDA1
is important for the activation of NF-κB in HaCat
cells, despite the fact that it is not required for
receptor binding. This suggests that the collagen
domain may activate EDA1 by oligomerization of
THD trimers, but alternative, non-mutually
exclusive hypotheses such as recruitment of
interaction partners or engagement of co-receptors
via the collagen domain could also account for
these observations.
Like EDA1-E245, Flag-EDA1-E245 failed to
activate NF-κB in HaCat cells. However, Flag-
EDA1-E245 could activate NF-κB when cross-
linked with anti-Flag antibodies (Fig. 3B and Fig.
S3B). Flag-tagged forms of EDA1-S160, with or
without in-frame deletions in the collagen domain,
were constitutively active and, as expected,
remained active in the presence of cross-linking
antibodies (Fig. 3B).
The Fc portion of IgG1 can functionally replace
the collagen domain of EDA - EDA1 constructs
were generated in which the collagen domain was
replaced with the Fc portion of human IgG1, with
or without insertion of a PreScission viral protease
site between the Fc and THD domains. Fusion of
the dimeric Fc fragment to trimeric EDA1 is
predicted to yield a hexameric protein containing 3
Fc moieties and 2 EDA1 trimers moieties, or even
higher oligomers (Fig. S3A, cartoon). Fc-EDA1-
E245 indeed eluted with high apparent molecular
weight by size exclusion chromatography,
consistent with an oligomeric form of the protein
(Fig. S4B), whereas treatment of the protease-
sensitive protein with PreScission protease
resulted in a quantitative release of EDA1-E245
that eluted at the position expected for a trimer
(Fig. S4A and C).
Uncleaved Fc-EDA1 activated NF-κB in HaCat
cells regardless of the presence or absence of the
protease site (Fig. 3C). This biological effect was
lost by physical separation of the Fc domain from
the EDA1 domain by cleavage with PreScission
protease, but, as expected, the same treatment did
not affect the protease-resistant Fc-EDA1 (Fig.
3C).
Taken together, these data are consistent with the
notion that the collagen domain renders EDA1
active by oligomerization. This function can be
mimicked by other oligomerization means, such as
Flag plus anti-Flag or fusion to the Fc portion of
IgG1.
The collagen domain potentiates the ability of
EDA1 to deliver oligomerization-dependent
signals in an engineered cell death assay by more
than 3 orders of magnitude - The HaCat assay
provided qualitative rather than quantitative
information on EDA1 activity and unfortunately
lacked robustness due to the relatively weak NF-
κB activation. We therefore thought to adapt a
well-characterized FasL-dependent cell death
assay to the purpose of measuring the functional
effect of EDA1 oligomerization. Thus, Fas-
deficient Jurkat T cells were transfected with a
chimeric receptor consisting of the extracellular
domain of EDAR fused to the transmembrane and
intracellular domains of Fas, and clones
undergoing apoptosis in an EDA1-sensitive
manner were selected.
Purified Flag-EDA1-S160, with or without in-
frame deletions in the collagen domain, killed
Jurkat EDAR:Fas cells with an IC50 of about 1
ng/ml, and was further activated only about 2-fold
in the presence of anti-Flag antibodies (Fig. 4 and
S5). Flag-EDA1-E245 displayed no activity by
itself in this assay, but this latency was overcome
in the presence of a cross-linking anti-Flag
antibody that increased the activity about 1000-
fold (Fig. 4). Interestingly, a 3 days pre-incubation
at 50°C did not affect the activity of Flag-EDA1-
S160 but decreased the activity of mutants with in-
frame deletions in the collagen domain roughly
10-fold. In line with the results obtained for NF-
κB activation in HaCat cells, we conclude that the
collagen domain of EDA1 fulfills a prominent role
to stimulate the signaling ability of EDA1 trimers
by oligomerization. Although deletions in the
collagen domain have no or little impact on the
activity of the protein, they decreased heat-
stability of the protein.
Taken together, these in vitro results demonstrate
that the collagen domain is a positive regulator of
EDA signals.
7EDA oligomerizes via its collagen domain - In
order to determine the oligomerization status of
EDA, its size was estimated by gel permeation
chromatography (Fig 5 and Table 1). The TNF
domain only (EDA1-E245) eluted at a size 3.2 x
that of the monomer, in line with the trimeric
structure determined by crystallography (23).
EDA1-S160, EDA1-S160 with mutation
KKKGKK>SASGAS in front of the collagen
domain and ACRP-EDA1-E245 (with the collagen
domain of ACRP30) had apparent multiplicities of
10.4, 14.4 and 16.4, respectively, suggesting that
they are bigger than trimers. However, size
exclusion chromatography overestimates the size
of asymmetric proteins, such as a protein
containing an elongated collagen domain.
Constructs of another TNF family ligand, FasL,
were therefore analyzed in parallel.  The TNF
homology domain of FasL taken alone eluted as
expected as a timer. FasL preceded by the collagen
domain of EDA1 and ACRP-FasL eluted with
apparent multiplicities of 9.7 and 12.7. As ACRP-
FasL was previously characterized as a hexamer
by electron microscopy (3), it can be concluded
that the presence of a collagen domain roughly
doubles the molecular weight determined by size
exclusion chromatography. When taking into
account this correction factor, estimated
multiplicities of EDA1-S160 and EDA1-S160
KKKGKK>SASGAS are about 5.2 and 7.2. This
is in any case bigger than a trimer and re-enforces
the assumption that EDA with a collagen domain
(from EDA or ACRP) forms multimers, probably
hexamers.
 Less than 4 h exposure to active EDA1 is
sufficient to induce tail hair formation in newborn,
EDA-deficient Tabby mice - Tabby mice have no
hair on the tail, a defect that can be corrected by ip
administration of Fc-EDA1-E245 in newborn mice
(12). As expected, tail hair formation induced by a
dose of 2 µg (2 mg/kg) Fc-EDA1-E245 was
abrogated by co-injection of an excess (37.5 µg) of
the decoy receptor EDAR-Fc. Interestingly,
delayed administration of EDAR-Fc for up to 1 h
prevented tail hair induction, but failed to do so
after 3.5 or 18 h (Fig. 6). This demonstrates that
less than 4 h exposure to active EDA1 is sufficient
to induce tail hair formation and suggests that this
experimental system should be relatively
insensitive to the half-live of EDA1.
EDA1 S160 is less active than EDA1 E245 in
vivo, in contrast to in vitro results - From the
combined in vitro results, we predicted that EDA-
S160 and EDA-E245 would be respectively active
and inactive when administered in vivo. To test
this hypothesis, newborn Tabby mice were treated
ip with increasing doses of EDA1-E245 or EDA1-
S160, and examined 3 to 4 weeks later for the
presence of hair on the tail. To our surprise, Flag-
EDA1-E245 was relatively efficient at inducing
development of tail hair in this setting, whereas
Flag-EDA1-S160 only induced few tail hairs, even
at the highest dose that we could test (6 mg/kg)
(Fig. 7 and data not shown). This suggests first
that EDAR signaling in vivo is possibly less
sensitive to the oligomerization status of the ligand
than expected from in vitro result and, second, that
Flag-EDA1-S160 may not freely gain access to the
receptor to initiate signaling.
EDA1 contains a heparan sulfate proteoglycan
(HSPG)-binding domain  - We noticed the
presence of a basic stretch of amino acid residues
at the N-terminus of the collagen domain, which is
conserved in EDA of mammals, birds, frogs and
even fishes (Fig. 8A). We wondered whether this
sequence could mediate binding to proteoglycans,
as shown previously to be the case for APRIL,
another TNF family member (24). Indeed, Flag-
EDA1-S160 that contains the basic region, but not
Flag-EDA1-E245 that lacks this region (and the
entire collagen domain), bound to proteoglycan-
positive 293T cells in a heparin-sensitive manner
(Fig. 8B). This binding was unlikely to be
mediated by the collagen domain itself, because in
frame deletions in the collagen domain did not
affect the binding, and because addition of an
heterologous collagen domain to the THD of
EDA1 (ACRP-EDA1) did not confer binding to
293T cells (Fig. 8B). These observations were
confirmed using Fc-EDA1 constructs, all of which
bound surface-expressed EDAR, but not the
EDA2-specific receptor XEDAR (25). Heparin-
sensitive binding of Fc-EDA1-S160 to 293T cells
was still observed after complete deletion of the
collagen domain (Δ181-234), but was completely
abolished by mutation of the conserved lysine
r e s i d u e s  o f  t h e  b a s i c  s t r e t c h
(KKKGKK>SASGAS) (Fig. 8C). Moreover, a
perfect correlation was observed between the
8presence of the basic sequence, and the ability of
EDA1 to interact with heparin (Fig. 8D). Finally
and similarly to APRIL, EDA1-S160 that contains
the basic sequence, but not EDA1-E245 in which
this region is absent or EDA1-S160
KKKGKK>SASGAS in which the basic site was
mutated, interacted specifically with Jurkat cells
transfected with syndecan1, syndecan2 or
glypican1, but not with mock-transfected cells, in
a heparin-inhibitable manner (Fig. S6).  These
results indicate that the basic region of EDA1
mediates binding to heparin and proteoglycans.
 The HSPG-binding domain of EDA1 attenuates
its activity in vivo - We wondered whether the
poor activity of EDA1-S160 in vivo after i p
administration could be explained by its
interaction with ubiquitously expressed HSPGs
that would sequester EDA1 away from developing
skin. We found that EDA1-S160 with a mutated
HSPG binding site (KKKGKK> SASGAS)
induced numerous tail hair in Tabby mice very
similar in density to those of a wild type mouse.
Such a phenotype was never achieved with wild
type EDA1-S160, containing the HSPG-binding
site, and was also stronger than that obtained with
EDA1-E245. The THD of EDA1 fused to the
collagen domain of ACRP (ACRP-EDA1) or to
the Fc domain of an immunoglobulin displayed in
vivo activities similar to EDA1-S160 with mutated
HSPG-binding site (Fig. 7  and S5). It is
noteworthy that mutation of the HSPG-binding
domain reduced both heat-stability and activity of
EDA1 on Jurkat EDAR:Fas cells, suggesting that
this region also contributes to the oligomerization
and stability of EDA1 (Fig. 4 and 7).
Taken together, these data are in line with the
hypothesis that the HSPG-binding site of EDA1-
S160 restricts its distribution in the organism.
DISCUSSION
About one in four mutations affecting EDA in
XLHED patients destroys the furin processing site,
indicating that EDA must be cleaved in order to
exert its activity (11,26). A similar proportion of
patients display point mutations or in frame
deletions in the collagen domain, pointing to its
essential but poorly characterized function.
We demonstrate that the collagen domain of
EDA functionally acts as a cross-linker of the
receptor-binding, trimeric THD domain. This
cross-linking function of the collagen domain can
be mimicked in several ways: antibody-mediated
cross-linking, fusion with the Fc portion of IgG1
or fusion with the collagen domain of
ACRP/adiponectin. All of these means rendered
the ligand as much as 1000-fold more active than
the THD alone in a surrogate assay measuring
activation of the oligomerization-dependent Fas
pathway. Size estimation of the EDA1 proteins
suggests that the collagen domain may serve as a
scaffold to bring at least two trimeric TNF
homology domains into the same molecule.
Some TNF family ligands such as TNF or
TWEAK are active as soluble trimeric ligands that
do not require further oligomerization in order to
signal through (at least one of) their receptors. In
contrast, membrane-bound ligands such as FasL or
CD40L are inactive in a soluble form, unless
oligomerized to meet the requirements of their
oligomerization-dependent receptors (2,3,27,28).
EDA appears be a "mixture" of both cases:
although it is released in a soluble form, it can
nevertheless activate its oligomerization-
dependent receptor because of a built-in
oligomerization domain.
In line with the hypothesis that the signaling
pathway downstream of EDAR is oligomerization-
dependent, activation of NF-κB in EDAR-positive
HaCat cells required the collagen domain of
EDA1, and oligomerization of EDA1 was also
required for its full activity when administered in
newborn Tabby mice. However, although trimeric
EDA1 was essentially inactive in in vitro assays, it
displayed some activity in vivo, suggesting that
the requirement of EDAR for oligomerized EDA1
in the context of hair development induced by a
recombinant ligand may not be as stringent as
initially thought.
 It only takes a few hours of exposure to EDA to
induce hair (and sweat gland, data not shown)
formation. However, as different ectodermal
appendages can develop at distinct time points,
agonists with longer half-lives should be able to
induce development of a wider spectrum of
structures. In this respect, agonist anti-EDAR
antibodies may prove to be particularly useful.
A short stretch of basic amino acids, mostly
encoded by the 23 bp exon 4 of EDA, precedes the
9collagen domain. It is striking that this feature, like
the furin site and the collagen domain, is
evolutionarily conserved between mammals, birds,
amphibians and fishes. We demonstrate here that
this sequence is an HSPG-binding site that impairs
in vivo activity of recombinant EDA. For
exogenously added EDA, this domain probably
results in the scavenging of EDA before it reaches
its target organ, an effect that can be partially
overcome by increasing the dose. For endogenous
EDA, HSPG binding probably restricts diffusion
and fine tunes its effects. HSPG binding generally
allows to establish concentration gradients for
proteins such as chemokines that coordinate
immune responses (29), or morphogens of the
Wnt, TGF-β, Hedgehog and FGF families of
ligands (30-33). We know that neither the HSPG-
binding domain nor the collagen domain of EDA1
are absolutely required to signal through EDAR in
vivo, as both can be replaced by the Fc-portion of
an IgG. However, even high dose treatments with
recombinant (12) or transgenic EDA (34,35) failed
to rescue subtle phenotypes such as kinks in
zigzag hairs, for which the dose and spatio-
temporal distribution of EDA1 is likely crucial
(36) and could well be regulated by the HSPG-
binding domain. If HSPG binding is functionally
relevant, one can wonder why it was never found
mutated in XLHED patients. First, exon 4 cannot
be deleted in frame. Second, mis-sense mutation
of just one of the basic residues is probably not
sufficient to completely abolish HSPG binding,
and may not translate into a phenotype severe
enough to be noticed. Alternatively, decreased
binding to HSPG may promote EDA signaling
rather than hampering it, by allowing an easier
access to the receptor. Interestingly, mutation of
the basic site not only abolished proteoglycan-
binding but also decreased heat stability,
suggesting that the basic sequence may also help
stabilizing the multimeric structure of EDA1.
 In frame deletions in the collagen domain that
deactivate EDA in XLHED patients have
apparently no impact on the cross-linking potential
of the collagen domain. Apart from the expected
slight reduction of MW by SDS-PAGE, these in-
frame deletions affected neither expression levels
upon transient transfection of the full length or
soluble proteins, nor proteolytic processing, nor
gel filtration elution profiles, nor the activity in
vitro, nor proteoglycan binding. It did however
display a modest effect on heat-stability of the
purified proteins. It is uncertain whether this
partial stability defect is sufficient to explain why
patients harboring these mutations are as severely
affected as those with non-sense mutations
resulting in total loss of EDA1 (11). Endogenous
levels of EDA1 are probably limiting, and a
decrease of EDA1 protein levels as a result of in-
frame deletions in the collagen domain, which
could be due to impaired binding to an
unidentified co-factor or to impaired stability of
the protein, may severely compromise formation
of ectodermal appendages. Recombinant proteins
lacking this domain are probably active because
they saturate the system, thus masking subtle
regulatory mechanisms.
These findings on the collagen and HSPG-
binding domains of EDA1 are relevant to the
choice of recombinant EDA that may potentially
be used for the early treatment of XL-HED: so far,
Fc-EDA1 remains the best agonist tested in vivo,
probably because of a numbers of reasons. Indeed,
the Fc favorably impacts the protein half-life in
addition to providing the protein with the potential
to be carried through maternal Fc-receptors. Also,
the Fc provides the necessary cross-linking and
alleviates the potentially deleterious effect of the
HSPG-binding domain. Finally, Fc-EDA1 is easier
to produce than proteins containing the collagen
domain of EDA.
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FIGURE LEGENDS
Fig.1. Schematic structure of the EDA1 constructs and related proteins used in this study.
Fig.2. EDA1 activates NF-κB in HaCat keratinocytes.
Panel A: HaCat keratinocytes were stained with Fc-EDA1-E245 (EDA1), in the presence or absence of
EDAR-COMP-Flag (sol. EDAR) or BCMA-COMP-Flag (sol. BCMA), and bound Fc-EDA1 was
monitored by FACS.
Panel B: HaCat cells were stimulated with 200 ng/ml of Fc-TNF (TNF) or 200 ng/ml of Fc-EDA1-E245
(EDA1), for the indicated period of time. Cell extracts were analyzed by Western blotting for the presence
of total IκBα (IκBα), phosphorylated IκBα (P-IκBα), or the loading control tubulin.
Fig.3. The collagen domain confers signaling capacity to the TNF domain of EDA1.
HaCat cells were stimulated for 20 min with various EDA1 constructs, and levels of phospho-IκBα, IκBα
and tubulin were visualized by Western blotting.
Panel A: Cells were stimulated with the indicated EDA1 proteins, which were obtained from Fc-
PreScission-EDA1 that had been cleaved with PreScission protease (see Suppl. Fig. S3).
Panel B: Cells were stimulated with supernatants of 293T cells transfected with full length EDA1, Flag-
tagged soluble EDA1, and deletion mutants thereof (see Suppl. Fig. S3). The stimulation was performed
in the presence or absence of anti-Flag antibody. Anti-Flag alone had no effect in this assay (data not
shown).
Panel C: Cells were stimulated with Fc-EDA1-E245 or Fc-PreScission-EDA1-E245 that had been treated
or not with PreScission protease (see Suppl. Fig. S4).
Fig. 4. The collagen domain of EDA1 is required for signaling through an oligomerization-dependent
reporter pathway.
A Jurkat T cell clone stably expressing a chimeric receptor consisting of the extracellular domain of
EDAR fused to the transmembrane and intracellular domains of Fas was treated for 16 h with varying
amounts of the indicated Flag-EDA1 (see Suppl. Fig. S5), in the presence (black symbols) or absence
(white symbols) of anti-Flag antibody. Flag-EDA1 was either used directly (squares) or pre-incubated for
3 days at 50°C prior to the assay (circles). Cell viability was monitored with the PMS/MTS assay.
Fig. 5. Size exclusion chromatography of EDA1 and FasL with or without collagen domains.
The indicated Flag-tagged proteins were fractionated by size exclusion chromatography on a Superdex
200 column. Active ligands were detected in the eluted fractions by means of a receptor-binding ELISA.
The elution position of molecular weight markers (in kDa) is indicated at the top of the elution profile.
The analysis of the data is shown in Table 1.
Fig. 6. Four hour exposure to Fc-EDA1 in newborn Tabby mice is sufficient to induce tail hair formation.
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Panel A: One day-old Tabby mice received ip 2 µg of Fc-EDA1, followed by 37.5 µg of EDAR-Fc at the
indicated time point. Pictures of the tail were taken 3 to 4 weeks later.
Panel B: Quantification of tail hair induction of the mice shown in Panel A. Mean ± std of 3 mice per
group. Tail hair induction score was determined as described in the legend to Fig. 7.
Fig. 7. Differential effects of the collagen domain and HSPG-binding domain of EDA1 in vitro and in
vivo.
Panel A: Jurkat EDAR:Fas cells were treated with different Flag-EDA1 at the indicated concentration as
described in the legend to Fig. 4.
Panel B: EDA-deficient Tabby mice were treated ip at day 1 after birth with the indicated dose of the
same Flag-EDA1 proteins used in panel A. Presence of hair on the tails was scored 3 to 4 weeks later
(Score 0: no hair, like Tabby; 0.5: very few hair; 1: sparse hair on ventral side; 2: numerous hair on
ventral side; 3: numerous hair on both sides; 4: dense hair on both sides, like wild type). Pictures of the
tail of three mice per group treated at the dose of 2.4 mg/kg are shown on the right. The ventral and dorsal
sides of the tail are facing left and right, respectively.
Fig. 8. EDA1 contains a heparan sulfate proteoglycan-binding sequence in front of the collagen domain.
Panel A: Sequence alignment around the mature N-terminus of EDA1. Conserved residues are
highlighted. The basic sequence responsible for HSPG binding and the collagen domain are indicated,
furin consensus sites are boxed and the furin cleavage site (of human EDA) is shown with an arrow head.
Species analyzed are Homo sapiens, Bos taurus, Canis familiaris, Mus musculus, Gallus gallus, Xenopus
tropicalis and Gasterosteus aculeatus.
Panel B: Untransfected, EDAR-negative 293T cells were stained with the indicated Flag-tagged versions
of EDA1 in the presence or absence of heparin, and analyzed by FACS.
Panel C: 293T cells were transfected with GPI-anchored extracellular domains of EDAR or XEDAR,
together with an EGFP tracer, and then stained with the indicated Fc-tagged versions of EDA1, in the
presence or absence of heparin. Cells were analyzed by 2 color FACS.
Panel D: The indicated Flag-tagged EDA1 constructs were pulled down with either EDAR-Fc (upper
panel) or with heparin-Sepharose (middle panel), and detected by western blot with an anti-Flag antibody.
Immunoprecipitated EDAR-Fc was revealed with an anti-human IgG antibody (lower panel). All EDA1
constructs bound to EDAR-Fc, but only those with an intact proteoglycan-binding region interacted with
heparin.
Table 1
Ligand Elution
volume
[ml]
Apparent
size
[kDa]
Theoretical
monomer
MWa [kDa]
Number of
globular
subunitsb
Estimated
number of
subunitsc
FasL 14.6 78 25.7 3.0 3.0
ACRP-FasL 11.25 447 35.1 12.7 6.4
EDA1-S160-242:FasL 11.85 327 33.7 9.7 4.8
EDA1-E245 15 63 19.7 3.2 3.2
EDA1-S160 12 302 29.1 10.4 5.2
EDA1-S160
KKKGKK>SASGAS
11.5 392 27.3 14.4 7.2
ACRP-EDA1-E245 11.25 447 27.3 16.4 8.2
a Theoretical molecular weight of the mature polypeptide + 7.5 kDa (for 3 N-linked glycans of  FasL) or +
1.3 kDa (for 1 N-linked glycan on half of the EDA1).
b Apparent size divided by the theoretical monomer MW.
c number of globular subunits divided by 2 if the molecule contains a collagen domain.
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SUPPLEMENTARY FIGURES
Fig. S1. Dose dependence of Fc-EDA1 staining of HaCat
cells.
HaCat cells were stained with Fc-EDA1-E245 is the presence
of heparin, followed by PE-coupled anti-human IgG and
analyzed by FACS. Staining was performed in a final volume
of 50 µl with the indicated volumes of 293T cell supernatant
(containing about 5 µg/ml of Fc-EDA1-E245 in Opti-MEM
medium). MFI: mean fluorescence intensity.
Fig. S2. Endogenous EDAR does not signal cell death. TNF-deficiency does not rescue the
Tabby phenotype.
Panel A: HaCat cell populations stably transduced with a dominant-negative form of Iκ-Bα or a
control vector were treated for 16 h with the indicated dose of Fc-TNF or Fc-EDA1-E245, after
which time cell viability was quantified with the PMS/MTS assay.
Panel B: Tabby mice were crossed with TNF-/- mice. The F2 generation was genotyped for the
presence of TNF, and screened morphologically for signs of ectodermal dysplasia such as lack of
tail hair and lack of hair behind the ears.
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Fig. S3. PreScission cleavage, Western blot analysis and quantification of several EDA1
proteins.
Panel A: The indicated proteins were produced as Fc-PreScission-EDA1 in supernatants of
transfected 293T cells.  They were captured on protein A-Sepharose, and eluted by cleavage with
Prescission protease. The same amount of EDA1 that served to stimulate HaCat cells in Fig.3A
was immunoprecipitated with EDAR-Fc/Protein A-Sepharose and analyzed by Western blotting
at various dilutions (1/1, 1/3, 1/9 and 1/27) with polyclonal anti-EDA AL166 anti-serum.  Known
amounts (20, 50, 100 and 200 ng) of purified, unprocessed Fc-EDA1-E245 were loaded for
quantification purpose. Note that EDA migrates as a doublet of glycosylated and non-
glycosylated proteins (1). Cartoons indicate the putative structural arrangement of the native
corresponding proteins
Panel B: Supernatants of 293T cells transfected with the indicated full length or Flag-tagged
EDA1 proteins. The same proteins served to stimulate HaCat cells in Fig. 3B. Proteins were
immunoprecipitated with EDAR-Fc, and the immunoprecipitates were analyzed by Western
blotting with polyclonal anti-EDA AL166 anti-serum.
1. Schneider, P., Street, S. L., Gaide, O., Hertig, S., Tardivel, A., Tschopp, J., Runkel, L.,
Alevizopoulos, K., Ferguson, B. M., and Zonana, J. (2001) J Biol Chem 276, 18819-18827
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Fig. S4. Cleavage of Fc-EDA1 with PreScission protease.
Panel A: Fc-PreScission-EDA1-E245, with a protease site engineered between the Fc and EDA1
moieties, was digested or not with PreScission protease and analyzed by Western blotting with
rabbit anti-EDA AL166 anti-serum. The same proteins served to stimulate HaCat cells in Fig. 3B.
Panel B: size exclusion chromatography of uncleaved Fc-PreScission-EDA1-E245 on Superdex-
200. Marks at the top indicate the fractions. Fractions selected for Western blotting with anti-
EDA1 AL166 anti-serum are numbered at the bottom. The size (in kDa) and elution position of
standard proteins for the chromatography and for the SDS-PAGE are indicated at the top and on
the left of the blot, respectively.
Panel C: as in B, but with Fc-PreScission-EDA1-E245 processed with PreScission protease.
Samples analyzed in A and C originated from different digestions. f: migration front.
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Fig. S5. Coomassie blue staining of Flag-EDA1 proteins.
Flag-tagged proteins were purified form conditioned supernatant of transiently transfected 293T
cells, and analyzed by SDS-PAGE and Coomassie blue staining. Note the reduction in molecular
weight in EDA1 proteins with in-frame deletions in the collagen domain. The following amounts
of Flag-EDA1 were loaded on the gel: ACRP-E245 (4 µg), E245 (3.5 µg), S160 (2.5 µg), S160
KKGKKK>SASGAS (3.5 µg), S160 Δ218-223 (2.5 µg), S160 Δ185-196 (3.5 µg). 5 µg of total
protein was loaded in each lane, of which 1 to 2.5 µg was contaminating bovine serum albumin
(not shown).
Fig. S6. EDA with an intact proteoglycan binding site interacts with proteoglycans.
Jurkat cells were electroporated with proteoglycan expression constructs together with an EGFP
tracer plasmid using the transfection solution V and the electoporation program O-17 (Amaxa
Biosystems). After electroporation, cells were cultured for 16 h, and then stained with the
indicated Fc-EDA constructs containing or not an intact proteoglycan-binding sequence, in the
presence or absence of heparin, and analyzed by FACS. APRIL constructs with (A88) or without
(H98) proteoglycan-binding sequence were included as controls. APRIL A88 and EDA-S160
bound cells in a heparin-inhibitable manner, whereas forms of EDA without the proteoglycan-
binding region did not.
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SUPPLEMENTARY TABLE
 Plasmid Designation Protein encoded Figure
ps515 EGFP Enhanced green fluorescent protein 8C
ps1752 EDA1 full hEDA1(aa 1-391) 3B,S3B
ps1753 EDA1 full Δ185-196 hEDA1 Δ185-196 (aa 1-391) 3B,S3B
ps1754 EDA1 full Δ218-223 hEDA1 Δ218-223 (aa 1-391) 3B,S3B
ps548 EDA1-E245 (short) Signal-Flag-Linker 1-VD-mEDA1 (aa 245-391) 3B,4,5,7,8B,S3B,S5,8D
ps1001 EDA1-S160 (long) Signal-Flag-Linker 1-hEDA1 (aa 160-391) 3B,4,5,7,8B,S3B,S5,8D
ps1002 EDA1-S160 Δ185-196 Signal-Flag-Linker 1-hEDA1 Δ185-196 (aa 160-391) 3B,4,8B,S3B,S5
ps1177 EDA1-S160 Δ218-223 Signal-Flag-Linker 1-hEDA1 Δ218-223 (aa 160-391) 3B,4,8B,S3B,S5
ps2266 EDA1-S160 KKKGKK
->SASGAS
Signal-Flag-Linker 1-hEDA1 KKKGKK>SASGAS (aa 160-391) 4,5,7,S5,8D
ps2343 EDA1-S160 Δ181-234 Signal-Flag-Linker 1-hEDA1 Δ181-234 (aa 160-391) 8D
ps2344 EDA1-S160 Δ181-234
KKKGKK->SASGAS
Signal-Flag-Linker 1-hEDA1 Δ181-234 KKKGKK>SASGAS (aa 160-391) 8D
ps869 ACRP-EDA1-E245 Signal-Flag-Linker 1 (D>H)-mACRP30 (aa 18-111)-LQ-mEDA1 (aa 245-391) 4,5,7,8B,S5
ps167 FasL Signal-Flag-Linker 1-hFasL (aa 139-281) 5
ps959 EDA1-S160-242 :FasL Signal-Flag-Linker 1-hEDA1 (aa 160-242)-MHVD-hFasL (aa 139-281) 5
ps579 ACRP-FasL Signal-Flag-Linker 1 (D>H)-mACRP30 (aa 18-111)-LQ-hFasL (aa 139-281) 5
ps1661 Fc-PS-EDA1-E245 Signal-LD-hFc (aa 245-470)-PreSci linker-EDA1 (aa 245-391) 2A,2B,3A,3C,8C,S1,S2A,S3A,S4,S6
ps1888 Fc-PS-EDA1-S160 Signal-LD-hFc (aa 245-470)-PreSci linker-EDA1 (aa 160-391) 3A,8C, S3A,S6
ps1707 Fc-PS-EDA1 Δ185-196 Signal-LD-hFc (aa 245-470)-PreSci linker-EDA1 Δ185-196 (aa 160-391) 3A, S3A
ps1708 Fc-PS-EDA1 Δ218-223 Signal-LD-hFc (aa 245-470)-PreSci linker-EDA1 Δ218-223 (aa 160-391) 3A, S3A
ps1943 Fc-PS-EDA1
KKKGKK->SASGAS
Signal-LD-hFc (aa 245-470)-PreSci linker-EDA1 KKKGKK>SASGAS (aa160-391) 8C,S6
ps2274 Fc-PS-EDA1 Δ181-234 Signal-LD-hFc (aa 245-470)-PreSci linker-EDA1 Δ181-234 (aa 160-391) 8C,S6
ps2287 Fc-PS-EDA1 Δ181-234
KKKGKK->SASGAS
Signal-LD-hFc (aa 245-470)-PreSci linker-EDA1 Δ181-234 KKKGKK>SASGAS (aa
160-391)
8C,S6
ps1938 Fc-EDA1-A238 HA signal-hFc (aa 245-470)-hEDA1 (aa 238-391). 6
ps1236 Fc-EDA1-E245 Signal-LD-hFc (aa 245-470)-Linker 2-GSLQVD-mEDA1 (aa 245-391) 3C
ps1181 Fc-TNF Signal-LD-hFc (aa 245-470)-Linker 2-GSLQ-hTNF (aa 85-233) 2B,3B,S2A
ps1252 sol. EDAR hEDAR (aa 1-183)-Linker 2-GGCC-hCOMP (aa 32-80)-EF-Flag 2A
ps1282 sol. BCMA Ig signal-PRGS-hBCMA (aa 2-54)-Linker 2-GGCC-hCOMP (aa 32-80)-EF-Flag 2A
ps1431 EDAR-GPI hEDAR (aa 1-183)-VD-hTRAILR3 (aa 157-259) 8C
ps1432 XEDAR-GPI Ig signal-DVT-hXEDAR (aa 1-134)-VD-hTRAILR3 (aa 157-259) 8C
ps930 EDAR-Fc hEDAR (aa 1-183)-VD-hFc (aa 245-470) S3, S5
ps1130 EDAR-PS-Fc hEDAR (aa 1-183)-VD-PreSci-hFc (aa 245-470) 6
ps2199 EDAR:Fas hEDAR (aa 1-183)-VD-hFas (aa 169-335) 4,7A
ps1889 IκBα-DN Flag-EFR-IκBα (aa 1-317) S32G S2A
ps1155 Fc-APRIL-A88 Signal-LD-hFc (aa 245-470)-linker 2-SLQ-hAPRIL (aa 88-233, from 2nd methionine) 6S
ps1307 Fc-APRIL-H98 Signal-LD-hFc (aa 245-470)-linker 2-PreSci-GSLQ-hAPRIL (aa 98-233, from 2nd methionine) 6S
ps1880 Syndecan-1 hSyndecan-1 (aa 1-308)-EFGSPGVD-VSV tag 6S
ps1666 Syndecan-2 hSyndecan-2 (aa 1-201)-VD-VSV tag 6S
ps1812 Glypican-1 Signal-VSV tag-Linker 1-VD-hGlypican-1 (aa24-558) 6S
Table S1. List of plasmids used in the study.
Amino acids are indicated with the one letter code or, for large stretches of sequence, by a written
description. Signal (signal peptide of haemaglutinin: MAIIYLILLFTAVRG ); Flag
(DYKDDDDK); VSV tag (YTDIEMNRLGK); Linker 1 (GPGQVQLQ); Linker 2
(RSPQPQPKPQPKPEPEG); PreSci (PreScission site: LEVLFQGP); PreSci linker
(RSPQPQPKPQPKPEPEG-LEVLFQGP-GSLQVD: the sequence in the middle corresponds to
the PreScission site); mEDA1 (SwissProt accession number O54693. Note that the protein
sequence of mouse and human EDA1 is identical for aa 245-391); hEDA1 (SwissProt accession
number Q92838); hFc (IgG1 encoded by GenBank accession number BC018747 or aa105-330 of
SwissProt accession number P01857); hTNF (SwissProt accession number P01375); hEDAR
(SwissProt accession number Q9UNE0); hTRAILR3 (SwissProt accession number O14798);
hCOMP (cartilage oligomeric matrix protein; SwissProt accession number P49747); Ig signal
(Signal peptide of mouse Ig, heavy chain: MNFGFSLIFLVLVLKGVQCEVKLV); hBCMA
(SwissProt accession number Q02223), hFas (SwissProt accession number P25445), hIκBα
(SwissProt accession number P25963), hAPRIL (SwissProt accession number O75888), hFasL
(SwissProt accession number P48023), hSyndecan-1 (SwissProt accession number P18827),
hSyndecan-2 (SwissProt accession number P34741), and hGlypican-1 (SwissProt accession
number P35052). The "" indicate predicted proteolytic cleavage sites by signal peptidase or
PreScission proteases.
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(SwissProt accession number Q02223), hFas (SwissProt accession number P25445), hIκBα
(SwissProt accession number P25963), hAPRIL (SwissProt accession number O75888), hFasL
(SwissProt accession number P48023), hSyndecan-1 (SwissProt accession number P18827),
hSyndecan-2 (SwissProt accession number P34741), and hGlypican-1 (SwissProt accession
number P35052). The "" indicate predicted proteolytic cleavage sites by signal peptidase or
PreScission proteases.
